GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that Nanette Cocero, Ph.D., has been appointed to its Board of Directors. Dr. Cocero is a recognized leader in the global pharmaceutical industry with broad commercial and business experience coupled with an extensive clinical and scientific background.
“The addition of Dr. Cocero continues to build on the pharmaceutical expertise within PharmaJet. Her extensive vaccine background and demonstrated leadership will be an asset to our company, and I look forward to her contributions as we drive global expansion and adoption of our innovative solutions,” said Chris Cappello, President, and CEO, PharmaJet.
“I am looking forward to joining PharmaJet’s distinguished BOD and leadership in their exciting journey ahead as we look to have a profound impact on global public health,” said Dr. Cocero.
With 25+ years of experience, Dr. Cocero was most recently the Global President of Pfizer Vaccines. In this role, she led a diverse, >$30B portfolio and drove the development, marketing, and delivery of innovative vaccines. Recognized for demonstrating an innovative mindset in healthcare delivery, she led the global commercialization and distribution of 2B+ doses of the Pfizer-BioNTech COVID-19 vaccine to 152 countries. Additionally, during her tenure, Nanette held senior positions across Pfizer’s core therapeutic areas including oncology, inflammation, immunology, internal medicine, and rare diseases. She also led business operations for 100+ countries across Latin America, Africa, the Middle East, and Asia. Prior to this, Nanette was a management consultant in the biotech and pharmaceutical industry. In addition, she sits on the board of HilleVax, a biopharmaceutical company focused on the development and commercialization of novel vaccines. Nanette holds a doctorate in Pharmacology from the University of Pennsylvania, an MBA from The Wharton Business School, and a Bachelor of Science degree in Chemistry from Cornell University.
The PharmaJet vision is to enable greater access to life-saving vaccines and pharmaceuticals globally. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information visit https://pharmajet.com. Follow us on LinkedIn.